Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2503
Source ID: NCT02689362
Associated Drug: Evogliptin
Title: Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)
Acronym: EVOLUTION
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Evogliptin|DRUG: Sitagliptin|DRUG: Placebo Evogliptin|DRUG: Placebo Sitagliptin
Outcome Measures: Primary: Absolute variation of the values obtained in the baseline for the HbA1c, 12 weeks after the start of the treatment | Secondary: Absolute variation of the values obtained in the baseline for the parameter, fasting blood glucose., 12 weeks after the start of the treatment|Absolute variation of the values obtained in the baseline for the parameter, body weight., 12 weeks after the start of the treatment
Sponsor/Collaborators: Sponsor: Eurofarma Laboratorios S.A.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 146
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2017-08-08
Completion Date: 2018-08-09
Results First Posted:
Last Update Posted: 2018-08-14
Locations: Centro de Estudos em Diabetes e Hipertensão, Fortaleza, Ceará, Brazil|Hospital Universitário João de Barros Barreto - HUJBB, Belém, Pará, Brazil|CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda, Rio de Janeiro, Brazil|Centro de Pesquisa Clínica em Diabetes - UNIFESP, São Paulo, Brazil|CEPIC - Centro Paulista de Investigação Clínica, São Paulo, Brazil|Clinica de Endocrinologia e Metabologia LTDA, São Paulo, Brazil|CPCLIN - Centro de Pesquisas Clinicas LTDA, São Paulo, Brazil|HCFMUSP, São Paulo, Brazil|IMA - Instituto de Pesquisa Clínica e Medicina Avançada Ltda, São Paulo, Brazil|IPEC - Instituto de Pesquisa Clínica Ltda, São Paulo, Brazil
URL: https://clinicaltrials.gov/show/NCT02689362